Uveitis and Posterior Ophthalmic Manifestations Following the SARS-CoV-2 (COVID-19) Vaccine

References

• Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–544. doi:10.1038/s41564-020-0695-z.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5.
   PubMed Web of Science ®Google Scholar
• Sen M, Honavar SG, Sharma N, Sachdev MS. COVID-19 and eye: a review of ophthalmic manifestations of COVID-19. Indian J Ophthalmol. 2021;69(3):488–509. doi:10.4103/ijo.IJO_297_21.
   PubMed Web of Science ®Google Scholar
• Benage M, Fraunfelder FW. Vaccine-associated uveitis. Mo Med. 2016;113:48–52.
   PubMedGoogle Scholar
• Cunningham ET Jr., Moorthy RS, Fraunfelder FW, Zierhut M. Vaccine-associated uveitis. Ocul Immunol Inflamm. 2019;27(4):517–520. doi:10.1080/09273948.2019.1626188.
   PubMed Web of Science ®Google Scholar
• Atas F, Kaya M, Saatci AO. Acute multifocal placoid pigment epitheliopathy-like presentation following the first dose of BNT162B2 COVID-19 vaccination. Ocul Immunol Inflamm. 2021;1–4. doi:10.1080/09273948.2021.1995763.
   PubMed Web of Science ®Google Scholar
• Franchi A, Rauchegger T, Palme C, et al. Two cases of acute macular neuroretinopathy associated with the adenovirus-based COVID-19 vaccine Vaxzevria (Astrazeneca). Ocul Immunol Inflamm. 2022:1–6. doi:10.1080/09273948.2022.2027463.
   PubMedGoogle Scholar
• Khochtali S, Krifa H, Zina S, et al. Multimodal imaging of acute foveolitis following COVID-19 vaccination. Ocul Immunol Inflamm. 2021:1–4. doi:10.1080/09273948.2021.1993270.
   Google Scholar
• Smith E, Tran T, Gillies A, et al. Multiple evanescent white dot syndrome following COVID-19 mRNA vaccination in two patients. Ocul Immunol Inflamm. 2022:1–4. doi:10.1080/09273948.2022.2032198.
   Web of Science ®Google Scholar
• Rabinovitch T, Ben-Arie-Weintrob Y, Hareuveni-Blum T, et al. Uveitis following the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association. Retina 2021.
   Google Scholar
• Centers for Disease Control and Prevention. Human Coronavirus Types. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html. Published February 15, 2020. Accessed August 10, 2021.
   Google Scholar
• Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193–292. doi:10.1016/S0065-3527(06)66005-3.
   PubMed Web of Science ®Google Scholar
• ElBagoury M, Tolba MM, Nasser HA, et al. The find of COVID-19 vaccine: challenges and opportunities. J Infect Public Health. 2021;14(3):389–416. doi:10.1016/j.jiph.2020.12.025.
   PubMed Web of Science ®Google Scholar
• Ura T, Yamashita A, Mizuki N, et al. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine. 2021;39(2):197–201. doi:10.1016/j.vaccine.2020.11.054.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Different COVID-19 Vaccines. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html. Published August 9, 2021. Accessed August 10, 2021.
   Google Scholar
• Jeyanathan M, Afkhami S, Smaill F, et al. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615–632. doi:10.1038/s41577-020-00434-6.
   PubMed Web of Science ®Google Scholar
• Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020;9. doi:10.7554/eLife.61312.
   PubMed Web of Science ®Google Scholar
• Karwaciak I, Sałkowska A, Karaś K, et al. Nucleocapsid and spike proteins of the coronavirus SARS-CoV-2 induce IL6 in monocytes and macrophages-potential implications for cytokine storm syndrome. Vaccines (Basel). 2021;9(1). doi:10.3390/vaccines9010054.
   PubMedGoogle Scholar
• Nussenblatt RB, Whitcup SM. Uveitis: Fundamentals and Clinical Practice. Maryland Heights, Missouri: Mosby/Elsevier; 2010.
   Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi:10.1038/clpt.1981.154.
   PubMed Web of Science ®Google Scholar
• The Population Estimates and Projections Program at Texas Demographics Center. Estimates of the total populations of counties and places in Texas for July 1, 2019 and January 1, 2020. https://demographics.texas.gov/Data/TPEPP/Estimates/. Published November 2020. Accessed January 17, 2022.
   Google Scholar
• Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States. https://data.cdc.gov/Vaccinations/COVID-19-Vaccinations-in-the-United-States-Jurisdi/unsk-b7fc. Published January 15, 2022. Accessed January 15, 2022.
   Google Scholar
• Joltikov KA, Lobo-Chan AM. Epidemiology and risk factors in non-infectious uveitis: a systematic review. Front Med (Lausanne). 2021;8:695904. doi:10.3389/fmed.2021.695904.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Lloyd MJ, Choi D, et al. Incidence and prevalence of uveitis in veterans affairs medical centers of the Pacific Northwest. Am J Ophthalmol. 2008;146(6):890–6.e8. doi:10.1016/j.ajo.2008.09.014.
   PubMed Web of Science ®Google Scholar
• Deepak P, Kim W, Paley MA, et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective Cohort study. Ann Intern Med. 2021;174(11):1572–1585. doi:10.7326/M21-1757.
   PubMedGoogle Scholar
• Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80(10):1330–1338. doi:10.1136/annrheumdis-2021-220647.
   PubMed Web of Science ®Google Scholar